Early Evaluation of Tumoral Response to Antiangiogenic Therapy by Arterial Spin Labeling Perfusion Magnetic Resonance Imaging and Susceptibility Weighted Imaging in a Patient With Recurrent Glioblastoma Receiving Bevacizumab

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Semiquantitative Assessment of Intratumoral Susceptibility Signals Using Non-Contrast-Enhanced High-Field High-Resolution Susceptibility-Weighted Imaging in Patients with Gliomas: Comparison with MR Perfusion Imaging

(2009) M.J. Park et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Susceptibility-Weighted Imaging: Technical Aspects and Clinical Applications, Part 2

(2009) S. Mittal et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker

(2009) Rajan Jain et al.   JOURNAL OF NEURO-ONCOLOGY

Susceptibility-Weighted Imaging: Technical Aspects and Clinical Applications, Part 1

(2008) E.M. Haacke et al.   AMERICAN JOURNAL OF NEURORADIOLOGY